Elsevier purchases oncology portfolio

Share this article:
Elsevier purchased Cancer Information Group's (CIG) oncology journal portfolio for an undisclosed sum. The acquisition, which includes six titles, will leave the journals' editors and editorial boards unchanged; David Allen, formerly CIG's managing editor, is now managing editor at Elsevier.
“The CIG titles are attractive because they provide high-quality peer-reviewed content—which Elsevier will seek to further improve in partnership with the editorial teams—in this dynamic area of research and clinical practice,” said Tom Reller, Elsevier's VP, global corporate relations, in an email. “Oncology is an important growth area for Elsevier, with increasing disease incidence, new therapeutic options for patients, and increasing numbers of papers published each year,” he said.
The titles, which include Clinical Breast Cancer, Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical Colorectal Cancer, Clinical Ovarian Cancer and Clinical Genitourinary Cancer, will be available online and in print, with advertising opportunities available in both formats, Reller said.
Glen Campbell, EVP, global medical research, Elsevier, said in a statement that “Authors will benefit from the upcoming release of enhanced online manuscript submission and review systems for the journals, as well as the range of author support tools provided by Elsevier.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?